NASDAQ:MDNA - Medicenna Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.50
  • Forecasted Upside: 156.06 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$3.71
▲ +0.01 (0.27%)
1 month | 3 months | 12 months
Get New Medicenna Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDNA

Average Price Target: $9.50
▲ +156.06% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Medicenna Therapeutics in the last 3 months. The average price target is $9.50, with a high forecast of $12.00 and a low forecast of $7.00. The average price target represents a 156.06% upside from the last price of $3.71.

Buy

The current consensus among 4 polled investment analysts is to buy stock in Medicenna Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/28/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/1/2021HC WainwrightLower Price TargetBuy$8.00 ➝ $7.00High
12/17/2020OppenheimerInitiated CoverageOutperform$12.00High
9/10/2020HC WainwrightInitiated CoverageBuy$8.00Low
8/24/2020Brookline Capital ManagementReiterated RatingBuyMedium
8/24/2020Bloom BurtonReiterated RatingBuyMedium
(Data available from 6/21/2016 forward)
Medicenna Therapeutics logo
Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Read More

Today's Range

Now: $3.71
Low: $3.66
High: $3.79

50 Day Range

MA: $3.72
Low: $3.24
High: $4.06

52 Week Range

Now: $3.71
Low: $3.14
High: $6.84

Volume

35,800 shs

Average Volume

181,664 shs

Market Capitalization

$198.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28

Frequently Asked Questions

What sell-side analysts currently cover shares of Medicenna Therapeutics?

The following sell-side analysts have issued research reports on Medicenna Therapeutics in the last twelve months: Bloom Burton, Brookline Capital Management, HC Wainwright, and Oppenheimer Holdings Inc..
View the latest analyst ratings for MDNA.

What is the current price target for Medicenna Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Medicenna Therapeutics in the last year. Their average twelve-month price target is $9.50, suggesting a possible upside of 156.1%. Oppenheimer Holdings Inc. has the highest price target set, predicting MDNA will reach $12.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $7.00 for Medicenna Therapeutics in the next year.
View the latest price targets for MDNA.

What is the current consensus analyst rating for Medicenna Therapeutics?

Medicenna Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MDNA will outperform the market and that investors should add to their positions of Medicenna Therapeutics.
View the latest ratings for MDNA.

What other companies compete with Medicenna Therapeutics?

How do I contact Medicenna Therapeutics' investor relations team?

Medicenna Therapeutics' physical mailing address is 200-1920 Yonge Street, Toronto A6, M4S 3E2. The company's listed phone number is 416-648-5555 and its investor relations email address is [email protected] The official website for Medicenna Therapeutics is www.medicenna.com.